Acute Kidney Injury (AKI) Disease Treatment Market - Forecasts from 2023 to 2028

The Acute Kidney Injury (AKI) disease treatment market is predicted to grow at a CAGR of 2.63% from US$31.070 billion in 2021 to US$37.253 billion by 2028.

The global market for acute kidney injury treatment is significantly influenced by the rising incidence of acute kidney damage. The National Kidney Foundation estimates that kidney illnesses impact about 37 million people in the US. Kidney injury risk has increased because of an aging population, poor diet, and heavy alcohol use. Acetaminophen and other drug overdoses, hepatitis, autoimmune disorders, and metabolic diseases are other causes contributing to the market's explosive expansion. Additionally, it is projected that rising healthcare costs and government measures to improve the healthcare system will boost market revenue. However, the market expansion is being hampered by the high cost of dialysis services and the low compliance from patients for long-term treatment plans.

The surge in lifestyle diseases.

Acute kidney injury results in sudden and temporary loss of the function of the kidney. This could occur due to several underlying diseases like diabetes and high blood pressure. A slew of diseases is cropping up due to changing lifestyles of people. Some of the prominent examples are diabetes, obesity, hypertension, and other liver or kidney-related diseases. The World Health Organization estimates that 60% of the variables affecting a person's health and quality of life are related to their way of living. People's health is being impacted by processed and junk food as well as poor eating habits. Additionally, a lack of exercise and movement increases the risk of dyspepsia and subsequent acute renal damage. People are developing addictions to drugs, alcohol, and smoking, all of which have detrimental effects on their health. Lack of physical movement and exercise is also increasing the likelihood of indigestion and consequent acute kidney injuries. People are getting addicted to alcohol, smoking, and drugs which also have adverse implications for their health. For instance, the International Society of Nephrology estimates that there are over 13.3 million cases of acute renal damage each year throughout the world. Globally, acute renal damage also results in 1.7 million deaths each year. AKI is present in about 1% of hospitalized patients in the United States.

Further, government efforts to speed up healthcare innovation are also accelerating market expansion.

The National Artificial Intelligence Research Resource Task Force was established in June 2021 as a result of an announcement made by the National Science Foundation and the White House Office of Science and Technology Policy. This task force will develop a roadmap for the expansion of educational resources and essential tools that will promote Al innovation across the country. Moreover, the industry's leading players are concentrating on the development of acute renal injury therapies, which is anticipated to propel the growth of the worldwide acute kidney injury treatment market during the forecast period.

By type of RRT, the AKI disease treatment market has been segmented into continuous and intermittent.

Unlike intermittent RRT, continuous dialysis involves the removal of water and waste from the blood takes place at a slow and steady rate which reduces the risk of this removal being poorly tolerated by patients who are hemodynamically unstable. Although this type of RRT is better suited for the treatment of AKI, their higher cost continues to be a major factor hindering their adoption across many economies where the affordability of expensive medical procedures is still a goal.

The growth of CRRT in the AKI treatment market is also supported by medical training programs and educational initiatives. Healthcare professionals, including nephrologists, intensivists, and critical care nurses, receive training and education on the principles and practical aspects of performing CRRT. Well-trained medical staff contributes to the wider adoption and successful implementation of CRRT in clinical settings.

North America and Europe held a significant market share of the market in 2021.

By geography, the global AKI disease treatment market is segmented as North America, South America, Europe, the Middle East and Africa, and Asia Pacific. APAC will witness a significant CAGR during the forecast period owing to the rising cases of chronic diseases in countries like China and India, along with the booming medical tourism industry across the region.

In North America, the high prevalence of diabetes in the U.S. is increasing the number of people with acute kidney injury. According to the Centers for Disease Control and Prevention (CDC), AKI is a significant public health problem in the United States, affecting over 500,000 people each year and resulting in more than 100,000 deaths. AKI is also associated with increased healthcare costs, with hospitalizations for AKI costing an estimated $10 billion annually in the US.

Moreover, there is increasing adoption of innovative treatment options, such as renal replacement therapies (RRTs), which include hemodialysis and peritoneal dialysis. These treatments are becoming more widely available and affordable, allowing more patients to access the care they need.

Market Developments:

• In September 2021, Sentien Biotechnologies, Inc., a clinical-stage technological advancement company developing novel cell therapy methods, announced a collaboration with the biomedical field Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services Assistant Secretary for Preparedness and Response, to test Sentien's ex vivo cell therapy, SBI-101, in patients with acute kidney injuries.
• The official introduction of the Carpediem cardio-renal pediatric dialysis emergency machine in the United States was announced by Medtronic plc, a world leader in medical equipment, services, and solutions, in December 2020. The first of its type Carpediem system is recommended for use in patients needing hemodialysis or hemofiltration therapy due to acute renal damage or fluid overload. It is designed to give patients who weigh between 2.5 and 10 kilograms continuous renal replacement treatment.

Market Segmentation:

By Component

• Treatment
• Drug Type
• Isotonic Solution
• Antibiotic
• Others
• Dialysis
• Diagnosis
• Urine Tests
• Blood Tests
• Glomerular Filtration Rate (GFR)
• Imaging tests
• Kidney Biopsy

By Type of RRT

• Continuous
• Intermittent

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• Japan
• South Korea
• India
• Others